tiprankstipranks

Morgan Stanley says FDA approval of Yeztugo ‘an expected positive’ for Gilead

After the FDA approved Gilead’s (GILD) Yeztugo for HIV prevention, Morgan Stanley analyst Terence Flynn said the label and pricing were in line with the firm’s expectations, calling the news “an expected positive.” The firm, which continues to see upside to the launch, reiterates an Overweight rating and $135 price target on Gilead shares.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1